WallStreetZenWallStreetZen

NASDAQ: AMRX
Amneal Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Amneal Pharmaceuticals revenue was $2.79B for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $730.5M, up 4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AMRX annual revenue was $2.8B, with 16.7% growth year-over-year.

AMRX past revenue growth

How has AMRX's revenue growth performed historically?

Company
16.73%
Industry
10.4%
Market
20.87%
AMRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AMRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AMRX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AMRX revenue history

Current Revenue
$2.8B
Current Earnings
-$116.9M
Current Profit Margin
-4.2%

Be the first to know when AMRX announces revenue.

AMRX Revenue History By Year

AMRX Yearly RevenueAMRX RevenueAMRX ChangeAMRX Revenue Growth
2024-12-31$2.79B$400.35M+16.73%
2023-12-31$2.39B$181.30M+8.20%
2022-12-31$2.21B$118.64M+5.67%
2021-12-31$2.09B$101.15M+5.08%
2020-12-31$1.99B$366.15M+22.51%
2019-12-31$1.63B-$36.62M-2.20%
2018-12-31$1.66B$629.34M+60.88%
2017-12-31$1.03B$15.43M+1.52%
2016-12-31$1.02B$151.95M+17.54%
2015-12-31$866.28M$80.66M+10.27%
2014-12-31$785.62MN/AN/A

1 of 1

Amneal Pharmaceuticals Revenue FAQ

What was AMRX's revenue last quarter?

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q4 2024 revenue of $730.52 million up 18.4% year over year. In the same quarter last year, Amneal Pharmaceuticals's revenue was $616.98 million.

What was Amneal Pharmaceuticals's revenue in 2024?

Amneal Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $2.79 billion, a 16.73% increase year over year.

How much does Amneal Pharmaceuticals make in a day?

Based on Amneal Pharmaceuticals annual revenue for the past five years, AMRX makes an average of $6,293,731.51 per day.

What was Amneal Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Amneal Pharmaceuticals's revenue has grown 16.73% year over year. This is 6.33 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.4%. Amneal Pharmaceuticals's revenue in the past year totaled $2.79 billion.

How much does Amneal Pharmaceuticals make in a year?

Amneal Pharmaceuticals's revenue by year for the past five years is:
  • Amneal Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $2.79 billion, a 16.73% increase year over year.
  • Amneal Pharmaceuticals's annual revenue for Dec 31, 2023 was $2.39 billion, a 8.2% increase from 2022.
  • Amneal Pharmaceuticals's annual revenue for 2022 was $2.21 billion, a 5.67% increase from 2021.
  • Amneal Pharmaceuticals's annual revenue for 2021 was $2.09 billion, a 5.08% increase from 2020.
  • Amneal Pharmaceuticals's annual revenue for 2020 was $1.99 billion, a 22.51% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.